XORTX Therapeutics Inc. (XRTX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Allen Warren Davidoff Ph.D. | Founder, CEO, President & Director | 286.97k | -- | 1960 |
| Mr. James Neville Fairbairn C.A., C.P.A., ICD.D | Chief Financial Officer | 56.66k | -- | 1963 |
| Dr. Stephen Haworth M.D., MRCP | Chief Medical Officer | 159.62k | -- | 1950 |
| Dr. Stacy Evans M.B.A., M.D. | Chief Business Officer | 208.19k | -- | 1974 |
| Nick Rigopoulos | Director of Communications | -- | -- | -- |
| Dr. David Sans M.B.A., Ph.D. | Director of Corporate Development | -- | -- | 1970 |
| Dr. David MacDonald Ph.D. | Consultant of Clinical Operations | -- | -- | 1964 |
| Ms. Charlotte May | Corporate Secretary | -- | -- | -- |
XORTX Therapeutics Inc.
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 2
Description
XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada.
Corporate Governance
Upcoming Events
November 12, 2024 at 9:00 PM UTC - November 18, 2024 at 9:00 PM UTC
XORTX Therapeutics Inc. Earnings Date